Adaptive Biotechnologies ADPT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's restricted cash?
- Adaptive Biotechnologies (ADPT) reported restricted cash of $2.71M in Q1 2026.
- How has Adaptive Biotechnologies's restricted cash changed year-over-year?
- Adaptive Biotechnologies's restricted cash decreased by 0.1% year-over-year, from $2.71M to $2.71M.
- What is the long-term trend for Adaptive Biotechnologies's restricted cash?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's restricted cash has grown at a 4.7% compound annual growth rate (CAGR), from $2.14M to $2.69M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.